Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)
 
 • Company Description   
Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

Number of Employees: 183

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.55 Daily Weekly Monthly
20 Day Moving Average: 144,191 shares
Shares Outstanding: 37.95 (millions)
Market Capitalization: $248.60 (millions)
Beta: -0.11
52 Week High: $21.79
52 Week Low: $6.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.70% -17.60%
12 Week -19.43% -32.01%
Year To Date -62.12% -64.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
One Design Center Place Suite 17-500
-
Boston,MA 02210
USA
ph: 857-520-9158
fax: -
investors@entradatx.com http://www.entradatx.com
 
 • General Corporate Information   
Officers
Dipal Doshi - Chief Executive Officer
Kush M. Parmar - Chairman
Kory Wentworth - Chief Financial Officer
Gina Chapman - Director
Peter S. Kim - Director

Peer Information
Entrada Therapeutics, Inc. (CORR.)
Entrada Therapeutics, Inc. (RSPI)
Entrada Therapeutics, Inc. (CGXP)
Entrada Therapeutics, Inc. (BGEN)
Entrada Therapeutics, Inc. (GTBP)
Entrada Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29384C108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 37.95
Most Recent Split Date: (:1)
Beta: -0.11
Market Capitalization: $248.60 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.18 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 8.09
PEG Ratio: -
Price Ratios
Price/Book: 0.60
Price/Cash Flow: 4.13
Price / Sales: 1.44
EPS Growth
vs. Year Ago Period: -161.76%
vs. Previous Quarter: -1,500.00%
Sales Growth
vs. Year Ago Period: -65.23%
vs. Previous Quarter: -45.03%
ROE
06/30/25 - -
03/31/25 - 5.84
12/31/24 - 16.93
ROA
06/30/25 - -
03/31/25 - 4.61
12/31/24 - 12.08
Current Ratio
06/30/25 - -
03/31/25 - 21.88
12/31/24 - 11.15
Quick Ratio
06/30/25 - -
03/31/25 - 21.88
12/31/24 - 11.15
Operating Margin
06/30/25 - -
03/31/25 - 14.39
12/31/24 - 31.14
Net Margin
06/30/25 - -
03/31/25 - 14.39
12/31/24 - 31.14
Pre-Tax Margin
06/30/25 - -
03/31/25 - 13.82
12/31/24 - 31.54
Book Value
06/30/25 - -
03/31/25 - 10.99
12/31/24 - 11.46
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©